Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117032
Author
Bando, Hiroshi Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs)
Oral semaglutide (Rybelsus)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Peptide Innovation for early diabetes treatment (PIONEER)
Adverse effects (AEs)
Content Type
Journal Article
Description
As one of the Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), oral semaglutide (Rybelsus) become first ingestible agent by absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). It was clinically investigated by Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) trials. Pharmacologically, blood concentration of semaglutide is kept higher when fasting time period after intake becomes longer. It is provided for increasing doses of 3 mg, 7 mg, 14 mg in every month. Rybelsus showed higher ratio of adverse effects (AEs), which include gastrointestinal dysfunction and headache. This agent is a novel delivery of therapeutic peptide and become life-changing beneficial agents for diabetic patients.
Journal Title
Journal of Diabetes, Obesity & Metabolism
Publisher
Yumed Text
Volume
5
Issue
1
Start Page
e108
Published Date
2022-04-24
Rights
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/).
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences